EP0918544A2 - Inhibiteurs polymeres de resorption d'acide biliaire a effet simultane d'adsorption de l'acide biliaire - Google Patents

Inhibiteurs polymeres de resorption d'acide biliaire a effet simultane d'adsorption de l'acide biliaire

Info

Publication number
EP0918544A2
EP0918544A2 EP97940028A EP97940028A EP0918544A2 EP 0918544 A2 EP0918544 A2 EP 0918544A2 EP 97940028 A EP97940028 A EP 97940028A EP 97940028 A EP97940028 A EP 97940028A EP 0918544 A2 EP0918544 A2 EP 0918544A2
Authority
EP
European Patent Office
Prior art keywords
alkylene
alkyl
compounds according
nhr
phenylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97940028A
Other languages
German (de)
English (en)
Inventor
Heinke Von Seggern
Werner Kramer
Günther Wess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Research and Technologies GmbH and Co KG
Original Assignee
Aventis Research and Technologies GmbH and Co KG
Hoechst Research and Technology Deutschland GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Research and Technologies GmbH and Co KG, Hoechst Research and Technology Deutschland GmbH and Co KG filed Critical Aventis Research and Technologies GmbH and Co KG
Publication of EP0918544A2 publication Critical patent/EP0918544A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F246/00—Copolymers in which the nature of only the monomers in minority is defined
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment

Definitions

  • the invention relates to polymers with bile acid absorption inhibitor and simultaneous bile acid adsorber effect, a process for their preparation and the use of these polymers as medicaments.
  • Bile acids and their salts are natural detergents and have an important physiological function in fat digestion and fat absorption. As end products of the choiesterin metabolism, they are synthesized in the liver, stored in the gallbladder and released from there as part of the bile into the intestine, where they exert their physiological effect. The major part (approx. 85-90%) of the secreted bile acids (approx. 16 g / day) is resorbed from the intestinal wall via the enterohepatic circulation, preferably in the terminal lieum, and transported back to the liver, ie recycled. Only 10-15% of the bile acids are excreted in the faeces.
  • a reduction in the amount of bile acid by post-synthesis of bile acids from cholesterol can be compensated to a certain extent via a control loop system.
  • a decrease in the liver cholesterol level leads to an increase in the absorption of cholesterol from the blood serum and thus lowers the cholesterol level in the blood serum.
  • the enterohepatic circulation can be interrupted and the serum cholesterol level in the blood can be reduced by suppressing the bile acid reabsorption by means of suitable inhibitors or bile acid adsorbers in the intestine. Too high a serum cholesterol level is considered to be of concern in medicine because it leads to atherosclerosis and thus the risk of heart attack increases. Therefore, there are many therapeutic approaches for the treatment of hypercholesterolemia.
  • One of these approaches is to interrupt the enterohepatic cycle. With this approach, all diseases can also are treated in which an inhibition of bile acid reabsorption in the small intestine appears desirable.
  • Non-absorbable polymers have been used therapeutically for some time to bind bile acids.
  • insoluble, mostly crosslinked polymers are used for this purpose, which contain quaternized nitrogen centers and act in a similar way to anion exchangers.
  • These polymers bind part of the bile acid anions present in the intestine via predominantly ionic interactions and transport them out of the intestine.
  • Commercial products of this type contain e.g. the active substances cholestyramine and colestipol. For example, they are used to treat hypercholesterolemia.
  • Bile acid absorption inhibitors (receptor blockers):
  • Bile acid receptor sites in the terminal ileum are blocked by molecules which, like the bile acids, can interact with the receptors but, unlike the bile acids, are not absorbed. Due to this receptor blockade, the bile acids can no longer be absorbed and are then excreted with the faeces. Examples of polymeric bile acid receptor blockers can be found in EP 0 549 967. This describes bile acid polymers and oligomers in which bile acid molecules are laterally linked to a polymer backbone.
  • the previously known adsorbers are not selective enough and also bind vitamins (eg vitamin K) and other physiologically important substances, so that deficiency symptoms (eg avitaminoses) can occur.
  • bile acid molecules or low-molecular bile acid absorption inhibitor molecules are bound covalently or via a spacer group to a polymer molecule, so that they are no longer self-absorbable but still retain their absorption-inhibiting effect.
  • the polymer is too large to be absorbed.
  • the polymer also contains bile acid adsorbent centers, e.g. B. quaternized nitrogen centers in the molecule.
  • Polymers of this type therefore have a dual effect. On the one hand, they act as polymeric bile acid absorption inhibitors due to the covalently firmly bound receptor blocker units and, on the other hand, as bile acid adsorbers.
  • the invention therefore relates to vinyl copolymers consisting of units of the formula
  • R 1 , R 2 , R 3 are hydrogen or CH 3 ;
  • R 4 , R 5 are hydrogen, (C r C 6 ) alkyl, (C r C 6 ) acyl; d 0.01 to 1.00; e 0 to 0.99; f 0 to 0.99; where d + e + f must be 1;
  • H is a bond, -CH 2 -, -Ar-, -Ar-CH 2 -, where Ar is phenylene, naphthylene m 1 to 18; n 1 to 18;
  • R 7 -OH, -O- (C r C e ) alkyl, -NH 2 ;
  • crosslinker selected from the group consisting of:
  • R 1 , R 2 , R 3 are hydrogen or CH 3 ;
  • R 4 , R 5 are hydrogen; d 0.01 to 1.00; e 0 to 0.99; f 0 to 0.99; where d + e + f must be 1;
  • H is a bond, -CH 2 -;
  • R 1 , R 2 , R 3 are hydrogen; R 4 , R 5 are hydrogen; d 0.01 to 1.00; e 0 to 0.99; f 0 to 0.99; where d + e + f must be 1;
  • H is a bond, -CH 2 -;
  • Physiologically compatible acid addition salts are understood as meaning compounds which are readily soluble, soluble and slightly soluble in water as defined in the "German Pharmacopoeia” (9th edition 1986, official edition, German Pharmacist Publishing House Stuttgart), page 19.
  • the hydrochlorides and sulfates of the compounds are preferred.
  • ammonium center is understood to mean a positively charged nitrogen atom (quaternized).
  • the invention further relates to a process for the preparation of the polymers consisting of units of the formula I.
  • the cholate-containing monomers were synthesized as described in the examples.
  • Attachment of a linker to cholic acid and subsequent polymer-analogous reaction with a polymer containing cholic acid is first mesylated with methanesulfonyl chloride in a basic medium.
  • the Mesyl group is a good leaving group and enables the attachment of side chains, eg a triethylene glycol unit, through nucleophilic substitution.
  • the free hydroxyl group of the triethylene glycol unit is then selectively activated by reaction with tosyl chloride.
  • the tosyl leaving group formed in this way enables polymer-analogous reaction with polymers containing amino groups, for example polyallylamine or polyvinylamine. (Example 1d).
  • the degree of substitution can be adjusted by changing the ratio of polyamine: cholic acid derivative.
  • Cholic acid is first converted into the active ester with p-nitrophenol.
  • the amido ether is then obtained by reaction with 2-methoxyethylamine (Example 3b). This is linked to an amino group-containing polymer as described in Method 1 via a linker.
  • An acrylic-substituted cholic acid derivative is reacted by radical copolymerization with a vinyl (preferably acrylic) monomer (see Example 5). Any ester groups still present in the cholate residue can be selectively saponified under basic conditions.
  • Allylamine (hydrochloride) and other radically polymerizable vinyl amines can be polymerized directly with acrylic-substituted cholic acid derivatives (Examples 11, 16).
  • an acrylic-substituted cholic acid derivative in alcoholic solution at pH 9-10 in a Michael addition with an amino group-containing polymer, e.g. a polyamine.
  • the present invention also relates to pharmaceutical preparations which contain one or more of the active compounds according to the invention and optionally further lipid-lowering agents.
  • the active compounds according to the invention are suitable for use as lipid-lowering drugs.
  • the active compounds according to the invention are used, for example, as pharmaceutical preparations, food additives, formulation auxiliaries, detergents, medications for influencing the enterohepatic circulation of bile acids, medications for influencing lipid absorption, medications for influencing serum cholesterol levels, medications for concentration-dependent inhibition of bile acid absorption in the gastrointestinal medication used to prevent arteriosclerotic symptoms.
  • Adduct of triethylene glycol with cholic acid Adduct of triethylene glycol with cholic acid:
  • Example 1a 6.1 g (12.5 mmol) of Example 1a were suspended in 25 ml (150 mmol) of triethylene glycol and dissolved by briefly heating to 100 ° C. 4.0 g (100 mmol) of magnesium oxide were added and the mixture was stirred at 100 ° C. for 5 h. After standing overnight, 100 ml of methylene chloride were added and the precipitate formed was suction filtered and washed with methylene chloride. The organic phase was washed with 200 ml of 2N aq. Hydrochloric acid extracted and then concentrated. Crude yield: 7.2 g.
  • Example 3b 4.1 g (9.9 mmol) of Example 3b were dissolved in 20 ml of pyridine. At 0 ° C 0.92 ml methanesulfonyl chloride was added and the mixture for 30 min at 0 ° C and 1 h at room temperature. touched. Ice was added to the mixture. Then 20 ml of conc. Sulfuric acid stirred in. The mixture was stirred for a further 5 minutes. The resulting precipitate was filtered off, washed with water and then taken up in dichloromethane. This solution was extracted with water. The organic phase was evaporated after drying over sodium sulfate. Crude yield: 4.7 g. The crude product was purified by column chromatography on silica gel (ethyl acetate). Yield: 2.9g (54%) Example 3c.
  • Example 9a To a solution of 55 mg (77 ⁇ mol) Example 9a and 17 mg (77 ⁇ mol) trimethylammonium propyl methacrylate chloride in 3 ml water were added 0.52 mg free radical initiator VA 044 (from Wako). The mixture was degassed and then stirred at 45 ° C for 70 h. The mixture was evaporated and the residue was dissolved in 10 ml of water and purified by ultrafiltration (membrane 5000 ⁇ ). After freeze-drying, 66 mg of Example 9b were obtained.
  • Example 9a Nitrogen was bubbled through a solution of 741 mg (1.0 mmol) of Example 9a in 3.5 ml of methanol for 30 minutes. The solution was then heated to 60 ° C. 10 mg of VA 044 radical initiator (from Wako) were added. The mixture was then stirred at 60 ° C. for 4 hours under a nitrogen atmosphere. It was then diluted with water and purified by ultrafiltration (membrane 5000 A). To exchange the counterion Br “ - Cl " , it was then washed twice with dilute aqueous NaCl solution and then twice with water. After freeze-drying, 456 mg were obtained.
  • VA 044 radical initiator from Wako
  • the product was isolated by ultrafiltration in water (membrane 5000A) and subsequent freeze-drying. Yield: 90 mg.
  • the bovine bile assay adsorption test measures the polymer's ability to adsorb bile acids.
  • the samples were prepared as follows:
  • aqueous solution which contains the following salts in the concentrations given below:
  • HPLC system from Kontron, consisting of three pumps and
  • Enzyme solution 3-alpha-hydroxysteroid dehydrogenase 0.5 units / ml
  • the batches are mixed and incubated for 2 hours at room temperature.
  • HPLC system from Kontron, consisting of three pumps and mixing chamber, autosampler, UV detector and evaluation unit with software MT2.
  • Mobile phase mobile phase A: ammonium carbamate buffer 0.019 M, with
  • TDC Taurodeoxycholate
  • GDC Glycodesoxycholate
  • TCDC Taurochenodeoxycholate
  • Rat intestine perfused in vivo examines the ability of the polymers to block bile acid reabsorption in the area of the ileum.
  • Rat intestine perfused in vivo The in vivo investigation was carried out as in FGJ Poelma et al. (J. Pharm. Sci. 78 (4), 285-89, 1989) - modifications of the test are given.
  • taurocholate and taurocholic acid or cholate and cholic acid are used synonymously.
  • the bile duct is dissected and a catheter is integrated (PE 50, Intramedic®).
  • PE 50 Intramedic®
  • an adapter for holding 100 ⁇ l disposable pipette tips was attached.
  • the bile is collected in these pipettes and filled into balanced Eppendorf reaction vessels at certain intervals.
  • the bile, as well as the medium samples are weighed out and aliquots are measured in the scintillation counter.
  • 10 ⁇ l sample are pipetted into a Sarstedt sample vessel, 58 x 22 mm, mixed with 10 ml Quickszint 212 (Zinsser GmbH, Frankfurt am Main, Germany) and counted in a Beckman 2800 ß counter after 30 min.
  • Wistar rats from our own breeding with an average body weight of 230-290 g are used as test animals.
  • the test animals are not starved before anesthesia (urethane 1 g / kg ip).
  • the animals are anesthetized on a temperature-controlled (constant 37 ° C) operating table (Medax), sheared on the abdominal side and then the abdominal wall is opened to the animals with an approx. 7 cm long incision.
  • a Luer adapter Feinmechanik Hoechst
  • the small intestine is tied in and tied further 13-14 cm to the beginning of the small intestine.
  • the contents of this intestinal segment are carefully rinsed out with 37 ° C warm isotonic saline.
  • the test solution is later instilled in this segment, the end of the jejunum beginning of the ileum.
  • the pump tubing is connected to the intestinal segment with two Luer adapters and the residual solution is filled in via a three-way valve (Pharmascal K 75a) and a 2 ml disposable syringe (Chirana) the medium is pumped at 0.25 ml / min
  • a three-way valve Pharmascal K 75a
  • a 2 ml disposable syringe Chirana
  • the medium is pumped at 0.25 ml / min
  • the bovine bile assay adsorption test shows that the polymers according to the invention have a significantly greater ability to adsorb bile acids than the substance of Example 15 from EP 0 549 967.
  • the polymers according to the invention have a similarly high ability to adsorb bile acids as cholestyramine.
  • the polymers according to the invention show an absorption-inhibiting effect of 36% to 60%.
  • cholestyramine shows a smaller absorption-inhibiting effect of 25%.
  • the polymers according to the invention are thus also superior in their action to cholestyramine since, in addition to their great ability to adsorb bile acids, they are themselves well bound to the bile acid receptor and thus show a resorption-inhibiting effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne des inhibiteurs polymères d'adsorption d'acide biliaire à effet simultané d'adsorption de l'acide biliaire, un procédé permettant de les préparer, des médicaments contenant lesdits composés et leur utilisation. L'invention concerne des copolymères vinyliques comportant les unités de la formule (I) dans laquelle R1 à R5, d, e, f, H, L, A, Y, Z et B ont la notation mentionnée dans la description, ainsi qu'un procédé permettant des les préparer. Les composés s'utilisent pour traiter des troubles du métabolisme lipidique.
EP97940028A 1996-08-19 1997-07-25 Inhibiteurs polymeres de resorption d'acide biliaire a effet simultane d'adsorption de l'acide biliaire Withdrawn EP0918544A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19633268A DE19633268A1 (de) 1996-08-19 1996-08-19 Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung
DE19633268 1996-08-19
PCT/EP1997/004049 WO1998007449A2 (fr) 1996-08-19 1997-07-25 Inhibiteurs polymeres de resorption d'acide biliaire a effet simultane d'adsorption de l'acide biliaire

Publications (1)

Publication Number Publication Date
EP0918544A2 true EP0918544A2 (fr) 1999-06-02

Family

ID=7802940

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97940028A Withdrawn EP0918544A2 (fr) 1996-08-19 1997-07-25 Inhibiteurs polymeres de resorption d'acide biliaire a effet simultane d'adsorption de l'acide biliaire

Country Status (5)

Country Link
EP (1) EP0918544A2 (fr)
JP (1) JP2000517356A (fr)
CA (1) CA2263671A1 (fr)
DE (1) DE19633268A1 (fr)
WO (1) WO1998007449A2 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3942846B2 (ja) * 2001-06-21 2007-07-11 独立行政法人科学技術振興機構 組織特異的トランスポーター阻害剤
CN1694964A (zh) * 2002-10-16 2005-11-09 协和梅迪克斯株式会社 高密度脂蛋白中的胆固醇的检测方法及试剂
ES2687027T3 (es) 2010-11-04 2018-10-23 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepáticas
DK2637646T3 (en) 2010-11-08 2016-08-29 Albireo Ab PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
EP3019559A4 (fr) 2013-08-22 2017-04-05 Sony Corporation Colorants colorés ou fluorescent hydrosolubles et procédés d'utilisation correspondants
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
EP3197459B1 (fr) * 2014-09-28 2025-02-12 Huahui Health Ltd. Dérivés d'acide biliaire polymère inhibant les virus de l'hépatite b et d et le transport de ntcp
EP3012252A1 (fr) 2014-10-24 2016-04-27 Ferring BV Formes crystallines d'Elobixibat
US11827661B2 (en) 2015-02-26 2023-11-28 Sony Group Corporation Water soluble fluorescent or colored dyes comprising conjugating groups
ES2874669T3 (es) 2016-02-09 2021-11-05 Albireo Ab Formulación oral de colestiramina y uso de la misma
WO2017138878A1 (fr) 2016-02-09 2017-08-17 Albireo Ab Formulation orale de cholestyramine et utilisation associée
CN108601739B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 考来烯胺丸剂及其制备方法
AU2017240154B2 (en) 2016-04-01 2021-08-12 Sony Group Corporation Ultra bright dimeric or polymeric dyes
WO2017177065A2 (fr) 2016-04-06 2017-10-12 Sony Corporation Colorants dimères ou polymères ultrabrillants comprenant des groupes lieurs d'espacement
EP3455300A1 (fr) 2016-05-11 2019-03-20 Sony Corporation Colorants polymères ou dimères ultra-brillants
JP7312929B2 (ja) 2016-07-29 2023-07-24 ソニーグループ株式会社 超明色二量体またはポリマー色素およびその調製のための方法
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
EP3664782B1 (fr) 2017-08-09 2025-01-29 Albireo AB Pastilles de cholestyramine, formulations orales de cholestyramine et leur utilisation médicale
WO2019071153A1 (fr) 2017-10-05 2019-04-11 Sony Corporation Médicaments dendritiques programmables
KR20260011205A (ko) 2017-10-05 2026-01-22 소니그룹주식회사 프로그램가능한 중합체성 약물
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
CN111465608A (zh) * 2017-12-13 2020-07-28 索尼公司 包含生物学活性化合物的离子型聚合物
US12539334B2 (en) 2018-01-12 2026-02-03 Sony Group Corporation Phosphoalkyl polymers comprising biologically active agents
EP3737417B1 (fr) 2018-01-12 2025-08-27 Sony Group Corporation Polymères phosphoalkyliques de ribose comprenant des composés biologiquement actifs
CN111565756A (zh) 2018-01-12 2020-08-21 索尼公司 包含生物活性化合物的具有刚性间隔基团的聚合物
KR102742386B1 (ko) 2018-03-19 2024-12-16 소니그룹주식회사 형광 신호 향상을 위한 2가 금속의 사용
CN118480073A (zh) 2018-03-21 2024-08-13 索尼公司 具有连接体基团的聚合串联染料
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
PL3810581T3 (pl) 2018-06-20 2025-04-28 Albireo Ab Modyfikacje kryształu odewiksibatu
JP7580689B2 (ja) 2018-06-27 2024-11-12 ソニーグループ株式会社 デオキシリボースを含むリンカー基を有するポリマー色素
KR20210032434A (ko) 2018-07-13 2021-03-24 소니 주식회사 유기인산염 단위를 포함하는 백본을 갖는 중합체성 염료
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CN118852054A (zh) 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
WO2021062176A2 (fr) 2019-09-26 2021-04-01 Sony Corporation Colorants en tandem polymères à groupes lieurs
EP4038081A1 (fr) 2019-09-30 2022-08-10 Sony Group Corporation Sondes nucléotidiques
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
WO2021110883A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs de l'acide biliaire
WO2021110887A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composés de benzothiazépine et leur utilisation en tant que modulateurs de l'acide biliaire
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
IL293379B2 (en) 2019-12-04 2026-04-01 Albireo Ab Benzothia(dia)azepine compounds and their use as bile acid modulators
EP4069247B1 (fr) 2019-12-04 2025-03-26 Albireo AB Composés de benzothiadiazépine et leur utilisation en tant que modulateurs de l'acide biliaire
WO2021110884A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composés de benzothia(di)azepine et leur utilisation en tant que modulateurs d'acide biliaire
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
EP4188541B1 (fr) 2020-08-03 2024-12-25 Albireo AB Composés de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire
CA3196488A1 (fr) 2020-11-12 2022-05-19 Albireo Ab Odevixibat pour le traitement de la cholestase intrahepatique familiale progressive (cifp)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
EP4256078A1 (fr) 2020-12-07 2023-10-11 Sony Group Corporation Conception de groupes coupleurs d'espacement pour l'amélioration de la luminosité de colorants dimères ou polymères
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
KR20250022025A (ko) 2022-06-09 2025-02-14 알비레오 에이비 간염 치료
WO2025146508A1 (fr) 2024-01-05 2025-07-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs d'acide biliaire
WO2025146507A1 (fr) 2024-01-05 2025-07-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs d'acide biliaire

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA08092A (fr) * 1984-05-11 1987-03-31 Bristol Myers Co Novel bile sequestrant resin and uses.
US5250524A (en) * 1990-12-06 1993-10-05 Hoechst Aktiengesellschaft Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals
EP0549967B1 (fr) * 1991-12-20 1996-03-13 Hoechst Aktiengesellschaft Polymères et oligomères des acides billiaires, procédé pour leur préparation et leur utilisation comme médicaments
NZ245504A (en) * 1991-12-20 1995-08-28 Hoechst Ag Bile acid derivatives containing an ethylenically unsaturated grouping
ATE159262T1 (de) * 1992-07-22 1997-11-15 Hoechst Ag Hydrophile zentren aufweisende polyvinylamin- derivate, verfahren zu ihrer herstellung sowie die verwendung der verbindungen als arzneimittel, wirkstoffträger und nahrungsmittelhilfsstoff
DK0580079T3 (da) * 1992-07-22 1997-06-30 Hoechst Ag Tværbundne, nitrogenholdige vinylcopolymerer, fremgangsmåde til deres fremstilling samt anvendelse af disse forbindelser
DE4234537A1 (de) * 1992-10-14 1994-04-21 Hoechst Ag Zubereitung, enthaltend Insulin und polymere Gallensäure
JPH06321785A (ja) * 1993-05-12 1994-11-22 Sekisui Chem Co Ltd 胆汁酸腸管吸収抑制剤
JPH06329543A (ja) * 1993-05-20 1994-11-29 Sekisui Chem Co Ltd 経口コレステロール低下剤
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9807449A2 *

Also Published As

Publication number Publication date
DE19633268A1 (de) 1998-02-26
WO1998007449A2 (fr) 1998-02-26
WO1998007449A3 (fr) 1998-06-25
CA2263671A1 (fr) 1998-02-26
JP2000517356A (ja) 2000-12-26

Similar Documents

Publication Publication Date Title
EP0918544A2 (fr) Inhibiteurs polymeres de resorption d'acide biliaire a effet simultane d'adsorption de l'acide biliaire
EP0549967B1 (fr) Polymères et oligomères des acides billiaires, procédé pour leur préparation et leur utilisation comme médicaments
DE69828067T2 (de) Kationische polymere zur bindung von toxinen
DE69812681T2 (de) Unsubstituierte polydiallylaminen zur behandlung von hypercholesterolemia
DE60225908T2 (de) Verwendung von colesevelam oder sevelamerhydrogenchlorid zur minderung des serumglukosegehaltes
EP0012804B1 (fr) Sels d'une résine échangeuse d'anion, non toxique, activée, capable d'établir des liaisons stables avec des acides biliaires et l'acide 2-(4'-(p-chlorobenzoyl)-phénoxy)-2-(méthyl)-propionique ainsi que compositions pharmaceutiques contenant ces sels
DE69326231T2 (de) Cholesterinspiegelsenkendes mittel
DE69425292T2 (de) Entzündungshemmendes und analgetisches äusserliches Pflaster-Präparat
DE69534686T2 (de) Antivirale dendrimere
DE60224052T2 (de) Aminpolymere zur behandlung von gicht und zur senkung des harnsäuregehaltes
EP0379161B1 (fr) Utilisation des dérivés alcoylés de polyéthylèneimine comme médicaments adsorbants d'acide biliaire et compositions pharmaceutiques
EP0548794B1 (fr) Dérivés de polyaspartamide adsorbant les acides biliaires, dérivés de polyaspartamide chargés d'acides biliaires et leur procédé de préparation et leur utilisation comme médicament
DE2835145A1 (de) Substanz zum behandeln von nierensteinen
DE2617524A1 (de) 3-eckige klammer auf n'-(3-halogenpropyl)-n'-methylamino eckige klammer zu -n,n,n-trimethyl-1-propanaminiumhalogenid und neue polymere
DE68911499T2 (de) Topisch anzuwendende Zubereitungen und Systeme zur transdermalen Verabreichung enthaltend 1-Isobutyl-1H-imidazo[4,5-c]chinolin-4-amine.
DE69532809T2 (de) Pharmazeutische präparate, insbesondere ovula, die viele verschiedene aktive bestandteile enthalten
CN103897079B (zh) 添加物甲基丙烯酸氨基烷基酯共聚物e的季铵化以改善药物渗透性和溶解度
DE112009005041T5 (de) Verfahren der Extraktzubereitung aus Longankern und die Anwendung des Longankernextrakts
DE2328580A1 (de) Arzneimittelformulierung mit kontrollierter verweilzeit im gastrischen bereich
DE4136324A1 (de) Dextranderivate als adsorptionsmittel fuer gallensaeuren, mit gallensaeuren beladene dextranderivate und verfahren zu deren herstellung sowie deren anwendung als arzneimittel
DE69429468T2 (de) Antikrebs-Mitoxantrone-Polymer Zusammensetzung
EP0068453A2 (fr) Compositions pour traiter les lithiases rénales
DE69906928T2 (de) Fettbindende polymere-lipasehemmer kombinationen zur behandlung von fettleibigkeit
DE2945788A1 (de) Arzneimittel und seine verwendung
DE4136325A1 (de) Cyclodextrinderivate als adsorptionsmittel fuer gallensaeure, mit gallensaeuren beladene cyclodextrinderivate und verfahren zu deren herstellung sowie deren anwendung als arzneimittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990319

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WESS, GUENTHER

Inventor name: KRAMER, WERNER

Inventor name: VON SEGGERN, HEINKE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20010323